ilmofosine的体内抗肿瘤活性。

In vivo antitumor activity of ilmofosine.

作者信息

Herrmann D B, Pahlke W, Opitz H G, Bicker U

机构信息

Boehringer Mannheim GmbH, Department of Immunopharmacology, F.R.G.

出版信息

Cancer Treat Rev. 1990 Sep;17(2-3):247-52. doi: 10.1016/0305-7372(90)90055-k.

DOI:10.1016/0305-7372(90)90055-k

PMID:2272040

Abstract

Ilmofosine is a cytostatic/cytotoxic thioether phospholipid derivative. The in vivo anti-tumour activity of this compound was investigated in a methylcholanthrene (MethA)-induced fibrosarcoma and in the 3Lewis-lung carcinoma systems, respectively. Ilmofosine showed antineoplastic and antimetastatic properties at oral doses ranging from 0.625 to 40 mg/kg/day. Combination of Ilmofosine (p.o.) together with either cyclophosphamide (p.o.) or cis-DDP (i.v.) resulted in synergistic effects in vivo. These results demonstrate the in vivo antitumour activity of Ilmofosine in two tumour systems. The data indicate that direct cytostatic/cytotoxic effects of Ilmofosine are mainly responsible for its antitumour activity in vivo and which are increased by other cytotoxics.

摘要

ilmofosine是一种具有细胞抑制/细胞毒性的硫醚磷脂衍生物。分别在甲基胆蒽（MethA）诱导的纤维肉瘤和3Lewis肺癌系统中研究了该化合物的体内抗肿瘤活性。ilmofosine在口服剂量为0.625至40 mg/kg/天的范围内显示出抗肿瘤和抗转移特性。ilmofosine（口服）与环磷酰胺（口服）或顺铂（静脉注射）联合使用在体内产生协同作用。这些结果证明了ilmofosine在两种肿瘤系统中的体内抗肿瘤活性。数据表明，ilmofosine的直接细胞抑制/细胞毒性作用主要是其体内抗肿瘤活性的原因，并且其他细胞毒性药物可增强这种作用。